Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment

Dahniel Sastow,John Mascarenhas,Douglas Tremblay

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 8|浏览0

暂无评分

摘要

•Thrombocytopenia in myelofibrosis is associated with worse outcomes.•Pacritinib is effective and tolerable in patients with severe thrombocytopenia.•Most disease modifying therapies in development exclude severe thrombocytopenia.•Thrombocytopenic MF patients represent an area of urgent unmet need.

查看译文

关键词

JAK inhibitors,Immunomodulators,Pacritinib,Ruxolitinib,Danazol

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要